Neo Ivy Capital Management Biomarin Pharmaceutical Inc Transaction History

Neo Ivy Capital Management

  • $505 Million
  • Q2 2024

A detailed history of Neo Ivy Capital Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Neo Ivy Capital Management holds 904 shares of BMRN stock, worth $63,542. This represents 0.01% of its overall portfolio holdings.

Number of Shares
904
Holding current value
$63,542
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024
BUY
$74.43 - $92.22 $67,284 - $83,366
904 New
904 $74,000
Q3 2022

Nov 15, 2022
BUY
$82.16 - $96.94 $4,518 - $5,331
55 Added 7.4%
798 $68,000
Q2 2022

Aug 16, 2022
BUY
$71.48 - $86.85 $53,109 - $64,529
743 New
743 $61,000
Q4 2021

Feb 15, 2022
SELL
$71.72 - $91.47 $74,875 - $95,494
-1,044 Closed
0 $0
Q3 2021

Nov 16, 2021
BUY
$74.77 - $85.47 $78,059 - $89,230
1,044 New
1,044 $129,000
Q2 2021

Aug 16, 2021
SELL
$75.51 - $84.79 $38,132 - $42,818
-505 Closed
0 $0
Q1 2021

Oct 07, 2021
SELL
$74.73 - $90.69 $13,600 - $16,505
-182 Reduced 26.49%
505 $38,000
Q4 2020

Feb 16, 2021
BUY
$72.61 - $90.2 $49,883 - $61,967
687 New
687 $60,000
Q3 2020

Nov 17, 2020
SELL
$71.87 - $131.03 $253,485 - $462,142
-3,527 Closed
0 $0
Q2 2020

Aug 17, 2020
BUY
$79.55 - $124.22 $197,522 - $308,438
2,483 Added 237.84%
3,527 $435,000
Q2 2020

Aug 17, 2020
BUY
$79.55 - $124.22 $54,730 - $85,463
688 Added 193.26%
1,044 $129,000
Q1 2020

May 15, 2020
BUY
$71.37 - $96.85 $25,407 - $34,478
356 New
356 $30,000
Q3 2019

Nov 21, 2019
SELL
$67.4 - $85.11 $237,719 - $300,182
-3,527 Closed
0 $0
Q2 2019

Aug 15, 2019
BUY
$80.35 - $93.9 $283,394 - $331,185
3,527 New
3,527 $302,000

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Neo Ivy Capital Management Portfolio

Follow Neo Ivy Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email